ABTA new way to dread a screening a little less
The FDA just approved Freenome’s SimpleScreen™ colorectal cancer blood-based screening test, and Abbott gets the keys to commercialize it in the U.S. That matters because colorectal cancer screening is one of those “you know you should do it, but...” health chores that a lot of people keep putting off.
The pitch is simple: make the test easier, and more people actually get screened. Abbott is betting that blood-based screening can help reach the up to 60 million Americans who are overdue. That’s not a niche tweak — that’s a giant pool of potential patients who may finally stop ghosting preventive care.
Why investors should care
This isn’t just a feel-good healthcare headline. It gives Abbott another commercial product to push into a market with real demand, plus it leans on two friendly tailwinds:
- Medicare coverage, which helps remove the “great test, but who pays?” problem
- American Cancer Society guidance, which lends credibility and supports wider adoption
In other words, Abbott isn’t trying to sell a science fair project. It’s trying to turn a new approval into actual clinical volume, which is where the money lives.
Big picture
For Abbott, this is the kind of move that can quietly expand the diagnostics business without the drama of a headline-grabbing blockbuster drug. If adoption sticks, you’re looking at a product with real public-health upside and a commercial runway that could get longer as blood-based screening becomes more mainstream.